Want to see GOVX full AI Analyst Report?

GeoVax Labs (GOVX) Earnings Dates, Call Summary & Reports

1,232 Followers

Earnings Data

Report Date

Aug 12, 2026

TBA (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

-2.16

Last Year’s EPS

-8.75

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 2 Analysts Ratings

Earnings Call Summary

Q3 2025

Earnings Call Date:Nov 13, 2025|

% Change Since:

Earnings Call Sentiment|Neutral

The earnings call highlighted significant advancements in the development and potential expedited approval of key vaccine candidates, along with increased industry interest and collaboration potential. However, financial challenges, including decreased revenue and increased net loss, present concerns. Overall, the positive development news is somewhat tempered by the financial performance.

Company Guidance

During the GeoVax Third Quarter 2025 Corporate Update Call, the company provided several key metrics regarding its progress and strategic initiatives. GeoVax highlighted its vaccine candidate GEO-MVA, which received expedited development guidance from the European Medicines Agency (EMA) to bypass Phase I and Phase II trials and proceed directly to a Phase III immuno-bridging trial. This advancement could lead to earlier marketing authorization and revenue generation. Financially, for the nine months ended September 30, 2025, GeoVax reported revenues of $2.5 million, a decrease from $3.1 million in 2024, primarily due to the termination of the BARDA Project NextGen contract. Research and development expenses decreased to $15.1 million from $16.1 million in the previous year, while general and administrative expenses increased to $4.6 million from $3.8 million. The company's net loss for the quarter was $6.3 million, slightly higher than $5.8 million in 2024. GeoVax remains focused on advancing its GEO-MVA vaccine and other product candidates, with significant interest in partnerships and collaborations to support development and commercialization.

Expedited Development Path for GEO-MVA

GeoVax received guidance from the European Medicines Agency to bypass Phase I and Phase II trials for GEO-MVA, proceeding directly to a Phase III immuno-bridging trial, potentially accelerating marketing authorization and revenue generation.

Increased Interest in Partnerships and Funding

The company is experiencing increased interest in partnerships and collaborations from industry players and nondilutive funding organizations, particularly for GEO-MVA and GEO-CM04S1.

Progress in Vaccine Manufacturing Process

GeoVax is advancing its MVA vaccine manufacturing process, which is expected to provide a significant advantage in the production of MVA-based vaccines.

Significant Interest in GEO-CM04S1

GEO-CM04S1 is gaining recognition as a needed vaccine for immunocompromised adults, with ongoing clinical trials and discussions for potential partnerships.

GeoVax Labs (GOVX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GOVX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 12, 2026	2026 (Q2)	-2.15 / -	-8.75	―	―	―
Apr 30, 2026	2026 (Q1)	-2.62 / -2.62	-11.25	76.71% (+8.63)	―	―
Mar 26, 2026	2025 (Q4)	-4.71 / -2.29	-21.892	89.54% (+19.60)	―	―
Nov 13, 2025	2025 (Q3)	-5.85 / -7.75	-22.75	65.93% (+15.00)	―
Jul 28, 2025	2025 (Q2)	-8.69 / -8.75	-49.75	82.41% (+41.00)	―
May 01, 2025	2025 (Q1)	-16.44 / -11.25	-61.75	81.78% (+50.50)	―
Mar 27, 2025	2024 (Q4)	-20.06 / -21.89	-98.5	77.77% (+76.61)	―
Nov 12, 2024	2024 (Q3)	-32.90 / -22.75	-120	81.04% (+97.25)	―
Aug 06, 2024	2024 (Q2)	-84.13 / -49.75	-82.5	39.70% (+32.75)	―
May 14, 2024	2024 (Q1)	-139.00 / -61.75	-56.25	-9.78% (-5.50)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GOVX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Apr 30, 2026	$1.05	$1.09	+3.81%
Mar 26, 2026	$1.50	$1.41	-6.00%
Nov 13, 2025	$11.72	$11.28	-3.82%
Jul 28, 2025	$18.50	$18.79	+1.55%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Geovax Labs, Inc. (GOVX) report earnings?

Geovax Labs, Inc. (GOVX) is schdueled to report earning on Aug 12, 2026, TBA (Confirmed).

What is Geovax Labs, Inc. (GOVX) earnings time?

Geovax Labs, Inc. (GOVX) earnings time is at Aug 12, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is GOVX EPS forecast?

GOVX EPS forecast for the fiscal quarter 2026 (Q2) is -2.16.